Drug diversion bill
A meeting of the legal counsels from PMA member companies on Oct. 16 turned down a proposal sponsored by Rep. Wyden (D-Ore.) to break the impasse over sampling violation sanctions. Wyden had worked on the issue one last time over the Columbus Day weekend after Chairman Dingell gave up on the issue Oct. 9.
You may also be interested in...
A report from the US FDA says the agency will focus on updating its premarket submission portal, training staff and taking additional steps to start taking in applications for ASCA pilot participant sponsors.
With a late-stage compound on its hands, MGB is currently in discussions with several biotech and pharma companies and also with venture capitalists to continue late-stage development of a novel antibiotic which could transform treatment of Clostridium difficile.
AZ and the EU are at loggerheads over supplies of the COVID-19 vaccine. On top of that, its marketing authorization will present dilemmas.